Jane Street Group, LLC Galectin Therapeutics Inc Transaction History

Jane Street Group, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.6 - $2.44 $4,825 - $7,359	3,016 Added 8.93%	36,785 $87,000
Q4 2023 Feb 14, 2024	BUY	$1.6 - $2.18 $54,030 - $73,616	33,769 New	33,769 $56,000
Q1 2023 May 15, 2023	BUY	$1.1 - $2.4 $5,636 - $12,297	5,124 Added 14.48%	40,522 $85,000
Q4 2022 Feb 14, 2023	BUY	$1.03 - $1.66 $36,459 - $58,760	35,398 New	35,398 $39,000
Q2 2021 Aug 16, 2021	BUY	$2.07 - $5.1 $23,045 - $56,778	11,133 New	11,133 $36,000
Q4 2019 Feb 14, 2020	SELL	$2.79 - $4.32 $66,538 - $103,027	-23,849 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$3.0 - $4.05 $71,547 - $96,588	23,849 New	23,849 $88,000
Q2 2019 Aug 15, 2019	SELL	$3.61 - $5.0 $79,524 - $110,145	-22,029 Closed	0 $0
Q1 2019 May 16, 2019	BUY	$3.86 - $6.02 $85,031 - $132,614	22,029 New	22,029 $113,000
Q3 2018 Nov 14, 2018	SELL	$3.68 - $6.93 $52,877 - $99,577	-14,369 Closed	0 $0
Q2 2018 Aug 15, 2018	BUY	$3.16 - $9.16 $45,406 - $131,620	14,369 New	14,369 $91,000

9.65M

1.16M

1.98M

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $123M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.